



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 22 Aug 2017 (#30)

[\[Click on blue hyperlink for further information\]](#)

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa de Vries [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)) to inform of your intent to apply.

## **Timelines:**

**Confirm your intent to apply as soon as possible, but not later than 30 days before the submission date.**

**All final documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

**The application will be submitted four (4) workdays before the application due date.**

## Important Notices

- **Changing policies impact NIH-funded studies involving human subjects.** For application due dates of January 25, 2018, and beyond, you will be required to use an updated application forms package (FORMS-E), which includes the new human subject and clinical trial form. This form requests human subject and clinical trials information at the study level using discrete form fields, which is a change from current practice. [Learn about the new form here](#).
- **Take a moment to answer these four questions about your current or proposed research:**
  - 1) Does the study involve human participants?
  - 2) Are the participants prospectively assigned to an intervention?
  - 3) Is the study designed to evaluate the effect of the intervention on the participants?
  - 4) Is the effect that will be evaluated a health-related biomedical or behavioral outcome?If the answer to all four questions is yes, then your proposed research meets [the NIH definition of a clinical trial](#)
- **The new [Clinical Trial Requirements for NIH Grantees and Contractors web page](#)**
- **Clarification of RFA-HD-18-009 "Global Network for Women's and Children's Health Research (UG1)" [\(NOT-HD-17-017\)](#)**  
*Eunice Kennedy Shriver National Institute of Child Health and Human Development*
- **Notice of Intent to Publish a Funding Opportunity Announcement for Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings (PATC3H) (UG3/UH3) [\(NOT-HD-17-021\)](#)**  
*Eunice Kennedy Shriver National Institute of Child Health and Human Development*
- **Clarification of RFA-HD-18-009 "Global Network for Women's and Children's Health Research (UG1)" [\(NOT-HD-17-017\)](#)**  
*Eunice Kennedy Shriver National Institute of Child Health and Human Development.* The purpose of this Notice is to broaden the eligibility of foreign partners allowed under RFA-HD-18-009 to include low-income as well as lower-middle-income countries in sub-Saharan Africa, South Asia, and Latin America as defined by the World Bank.
- **Notice of NIMH's Interest in Pediatric Pharmacologic Trials in Autism Spectrum Disorders, directed at testing selective GABAergic agents [\(NOT-MH-17-044\)](#)**  
*National Institute of Mental Health*

## 1. Biology of Lung, and Head and Neck Preneoplasias

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-17-459\)](#)  
[\(PA-17-460\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies. Clinical Trial Not Allowed.

**Budget:** R01 -Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. R21-Direct costs are limited to \$275,000 over a two-year project period, with no more than \$200,000 in direct costs allowed in any single year.

## 2. National Institute of Neurological Disorders and Stroke (NINDS) CREATE Bio Optimization Track for Biologics

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-17-456\)](#)

**Type:** U01

**Application Due Date:** February 13, 2018; July 18, 2018. Aids dates: May 7, 2018; September 7, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) supports the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA). **Cooperative**

**Agreement:** A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA. **IMPORTANT:** Per [NOT-OD-17-062](#) updated application forms (FORMS-E) will be used for this opportunity. The updated forms are not yet available and will be posted no later than November 10, 2017.

**Budget:** Application budgets are not limited but must reflect the actual needs of the proposed project. Budgets for these projects will normally remain under \$500,000 in direct costs in any given year and fluctuate over the funding period based on the stage of the project. The project period may not exceed 5 years

**Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)

**R01 – NIH Research Project Grant Program:** most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

**R21 – NIH Exploratory/Developmental Research Grant:** encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

**R03 – NIH Small Grant Program:** limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).